Why Modern Pharmacology CME Will Change the Way You Manage Weight Loss and Cardio-Metabolic Patients

Price: $399.99
Duration of Access: 30 Months
Deliverables: 12 AAPA Category 1 Self-Assessment CME Credits, 120 Question Bank, and Pharmacology Lecture Videos

Staying current with the rapid evolution of metabolic medicine is no longer optional for the modern clinician. The emergence of GLP-1 receptor agonists and dual GIP/GLP-1 agonists has redefined the standard of care for obesity, type 2 diabetes, and cardiovascular risk management. Our Pharmacology CME Review Package provides the precise clinical data required to navigate these foundational therapies.

This course is designed specifically for Physician Assistants, offering 12 hours of AAPA Category 1 Self-Assessment CME credit. Because the NCCPA applies a 50% weighting to self-assessment credits, this package effectively provides 18 hours of credit toward your certification maintenance. Nurse practitioners can also find value in this course, as many state boards and the AANPCB accept AAPA Category 1 credits. Physicians may use this course to claim Category 2 CME.

Beyond the clinical content, this package offers a strategic way to utilize your professional development funds. You can add an Amazon or Apple Gift Card ranging from $100 to $1500 to your purchase. The gift card cost is integrated into the total package, allowing you to maximize your CME budget and enrich your personal education library.

---

Clinical Pharmacology: Case-Based Assessment

Case 1: Obesity and Cardiovascular Risk Management

Your patient is a 54-year-old male with a BMI of 34 kg/m², hypertension, and established coronary artery disease (post-PCI two years ago). He does not have type 2 diabetes; his latest A1c is 5.6%. He has attempted lifestyle modifications for six months with a total weight loss of only 2%. He asks about initiating pharmacotherapy to reduce his risk of future myocardial infarction.

Which of the following medications has been shown to reduce the risk of major adverse cardiovascular events (MACE) in patients with obesity and established cardiovascular disease without diabetes?

A. Phentermine/Topiramate ER
B. Semaglutide 2.4 mg (Wegovy)
C. Liraglutide 3.0 mg (Saxenda)
D. Orlistat

Correct Answer: B. Semaglutide 2.4 mg (Wegovy)

Explanation: The SELECT trial demonstrated that Semaglutide 2.4 mg reduced the risk of MACE (non-fatal MI, non-fatal stroke, or CV death) by 20% in patients with a BMI ≥27 kg/m² and established cardiovascular disease, even in the absence of diabetes. While Phentermine/Topiramate and Orlistat are FDA-approved for weight loss, they do not have the same level of evidence for cardiovascular risk reduction. Liraglutide has shown CV benefit in the LEADER trial, but that was specifically in patients with type 2 diabetes, and the magnitude of weight loss and MACE reduction in the obesity-only population is more robustly documented with semaglutide 2.4 mg.

Case 2: Heart Failure and Metabolic Syndromes

Your patient is a 68-year-old female with a history of Heart Failure with Preserved Ejection Fraction (HFpEF), BMI of 38 kg/m², and Type 2 Diabetes. Her current medications include Metformin, Lisinopril, and Carvedilol. Her eGFR is 52 mL/min/1.73m². Despite adherence, she continues to have peripheral edema and dyspnea on exertion.

According to current guidelines, which class of medication should be prioritized for both her HFpEF management and renal protection?

A. SGLT2 Inhibitors (e.g., Empagliflozin)
B. DPP-4 Inhibitors (e.g., Sitagliptin)
C. Sulfonylureas (e.g., Glipizide)
D. Thiazolidinediones (e.g., Pioglitazone)

Correct Answer: A. SGLT2 Inhibitors (e.g., Empagliflozin)

Explanation: SGLT2 inhibitors are now foundational therapy for patients with heart failure (both HFrEF and HFpEF) and chronic kidney disease (CKD). Trials like EMPEROR-Preserved and DELIVER have confirmed that these agents reduce the risk of CV death and HF hospitalizations regardless of diabetes status. Furthermore, they provide significant renal protection by reducing intraglomerular pressure. Thiazolidinediones should be avoided in patients with heart failure due to the risk of fluid retention. DPP-4 inhibitors and Sulfonylureas offer no cardiovascular or renal protection benefits.

Case 3: Adverse Event Monitoring in Dual Therapy

A 45-year-old female with Type 2 Diabetes and obesity is currently taking Tirzepatide (GIP/GLP-1 agonist) and Empagliflozin (SGLT2 inhibitor). She presents to the clinic with persistent nausea, vomiting, and abdominal pain after a 24-hour period of poor oral intake due to a viral illness. Her blood glucose is 142 mg/dL, but she appears clinically dehydrated and ill.

What is the most critical condition to exclude in this patient given her current medication regimen and presentation?

A. Acute Pancreatitis
B. Euglycemic Diabetic Ketoacidosis (EDKA)
C. Tirzepatide-induced Gastroparesis
D. Small Bowel Obstruction

Correct Answer: B. Euglycemic Diabetic Ketoacidosis (EDKA)

Explanation: Euglycemic Diabetic Ketoacidosis (EDKA) is a serious potential side effect of SGLT2 inhibitors, particularly when the patient is in a catabolic state (illness, fasting, or prolonged vomiting). Because the glucose level is often near-normal or only mildly elevated (<250 mg/dL), the diagnosis is frequently delayed. Clinicians must check blood or urine ketones and an arterial/venous blood gas to evaluate for metabolic acidosis. While GLP-1s/GIPs increase the risk of GI side effects and rarely pancreatitis, the presence of an SGLT2 inhibitor in an acutely ill patient with vomiting makes EDKA the most life-threatening priority to rule out.

---

Maximizing Your CME Credit

Clinicians preparing for the PANRE or PANRE-LA must have a firm grasp of these pharmacologic principles. The NCCPA Blueprint emphasizes the management of metabolic and cardiovascular disorders, which accounts for a significant portion of the exam content.

If you are looking for a more comprehensive review that includes 100 hours of AAPA Category 1 Credit, our PANRE Review Course is the standard for PAs. It covers all major body systems: from Cardiology and Pulmonology to Endocrinology and Neurology: ensuring you are prepared for both clinical practice and your recertification exam.

Our content is written by physician assistants for physician assistants. This peer-led approach ensures that the depth of information is practical, evidence-based, and directly applicable to the clinical challenges you face daily.

Summary of Offerings:

• Pharmacology Course: 12 Hours AAPA Cat 1 Credit (18 Hours logged).
• PANRE Review Course: 100 Hours AAPA Cat 1 Credit.
• Gift Card Options: Amazon and Apple Gift Cards up to $1500.
• Target Audience: PAs (Cat 1), NPs (AAPA accepted), Physicians (Cat 2).

Enroll in the Pharmacology CME Review Course today to stay at the forefront of metabolic medicine.